Sinovac Biotech, a vaccine maker headquartered in Beijing, reported positive, though preliminary top-line data from the Phase III clinical trial for its Enterovirus 71 vaccine, a human innoculation that protects against hand, foot and mouth disease. The vaccine, which was administered to infants from 6 to 35 months, produced an efficacy of 95.4%. More details.... Stock Symbol: (NSDQ: SVA) Share this with colleagues: // //